01-26-05

| 1-" | | | | | U I | | , | | / | | |
|-----|-------------------------------------|-------------|--|---|----------------------------|--------------------------|-----------------------|-------------|----------|--|--|
| | | | | | Docket Numbe | 4-30583A/ | 30967/C1 | | | | |
| | 2 | | | FILING BY "EXPRES | S MAIL" UNDE | R 37 CFR 1.10 |) | | | | |
| | ŝ | | | 635646842US | January 25, 2001 | | | | | | |
| | = | | Express Ma | il Label Number | Date of Deposit | | | | | | |
| == | 6 | | Assistant Commission Box Patent Applicati Washington, DC 202 | on | I TRANS | MITTAL | AND FEE | SHEET | U.S. PTO | | |
| | Tran | smi nati | tted herewith fo onal Applicatio | or filing under 37 C n No. PCT/EP99/0 | FR §1.53(t 05316, filed | o)(1) is a d July 26, | continuatior 1999. | of prior | 10960 | | |
| | Applicant (or identifier): AMLOT | | | AMLOT ET AL. | | | | | | | |
| | Title: | | | USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR SKIN DISEASES | | | | | | | |
| | Enclosed are: | | | | | | | | | | |
| | 1. 2. 3. | | Specification (Including Claims and Abstract) - 13 pages Drawings - sheets Declaration and Power of Attorney a. ☐ Unexecuted (original or copy) b. ☐ Copy from a prior application (signed or with indication that original was signed) i. ☐ Deletion of Inventors Signed statement attached deleting inventor(s) named in the prior application Incorporation By Reference The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. | | | | | | | | |
| | 4. | | | | | | | | | | |
| | 5. 6. | | Microfiche Cor Nucleotide and Computer Paper Cop | nputer Program (ap d/or Amino Acid Seq Readable Copy by | uence Subn | | | | | | |
| | 7. 8. 9. 10. 11. 12. | | Preliminary An Assignment Pa English Transla Information Dis | apers (Cover Sheet ation of sclosure Statement of Priority Documer | & Document | | | | | | |
| | | App ide | olication No. in t | n invention or specion he event of a restric ntially similar to that | tion or elect | ion of spec | cies requireme | ent that is | | | |
| | | | | | | | | | | | |

Filing fee calculation:

Before calculating the filing fee, please enter the enclosed Preliminary Amendment.

Before calculating the filing fee, please cancel claims

G

| | - |
|------------|---|
| ⇒ € | - |
| ₩ | |
| 35 | L |
| S = 8 | |
| | L |
| F | l |
| | L |
| | г |

| 1 | Basic Filir | Basic Filing Fee | | | | | | | | \$ 710 |
|-----|---------------------------------------|-----------------------|-----------------|-----|-----------------|---|------|----|-----------|-----------|
| . ! | Multiple Dependent Claim Fee (\$ 270) | | | | | | | | \$ | |
| 2 | Foreign Language Surcharge (\$ 130) | | | | | | | | \$ | |
| 5 | | For | Number Filed | | Number Extra | | Rate | | | |
| | Extra Claims | Total Claims | 10 | -20 | 0 | x | \$ | 18 | = | \$ |
| | | Independent Claims | 1 | -3 | 0 | х | \$ | 80 | = | \$ |
| | | TOTAL FILING FEE | | | | | | | \$ 710 | |

☑ Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$710. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie

Novartis Corporation

Patent and Trademark Dept.

564 Morris Avenue

Summit. NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (908) 522-6955.

Respectfully submitted,

Date: January 25, 2001

Diane E. Furman Attorney for Applicants Reg. No. 31,104 Tel. No. (908) 522-6924